Plastic Surgery Practice July 2014
Two new studies suggest that the more moles a woman has, the greater her risk for developing breast cancer. In one study, women with 15 or more moles on a single arm were 35% more likely to develop breast cancer than women with no moles.
Exactly how moles are linked to breast cancer development is unknown, and the link may have something to do with estrogen. The new reports were published in PLOS Medicine.
A term coined by Tracy Drumm of Chicago’s IF Marketing in her new book, Drive: The Power of Execution. Commun-i-clutter refers to the avalanche of marketing information and advertisements that prospective patients are inundated with from aesthetic practices just like yours. So how do you break through the clutter and let your message be heard? You’ll have to read Drive to find out. It’s available here.
World Cup fever is gripping the nation, and millions of us remain glued to the television watching the likes of Portugal’s Cristiano Ronaldo and Brazil’s Neymar dribble, head, and score with relative ease. Although the pros make it look easy, Brazilian plastic surgeons warn colleagues that soccer players—particularly, amateur ones—are at risk for serious facial injuries. “Due to exposure and the lack of protection for the face, the occasional maxillofacial trauma sustained during soccer games often entails serious facial injuries requiring hospital admissions and invasive procedures,” write researchers led by Dov Charles Goldenberg, MD, PhD, of University of São Paulo in Plastic and Reconstructive Surgery—Global Open®. “Missed diagnosis or delayed treatment can lead to facial deformities and functional problems in the physiological actions of breathing, vision, and chewing.”
The 2014 World Cup takes place in Brazil from June 12 through July 13, 2014.
As most of the world waits to see what the final outcome will be in Valeant’s bid to take over Allergan, the Canadian pharma company has scored two US Food and Drug Administration nods: Restylane® Silk Injectable Gel with 0.3% Lidocaine for lip filling and fine lip lines, and Jublia® (efinaconazole 10% topical solution) for toenail onychomycosis.
Most Team Allergan players are quick to point out that Valeant isn’t all that vested in Research and Development, but the two new approvals may suggest otherwise. The jury is still out on what is very much a moving target.
Original citation for this article: PSP Spotlight. Plastic Surgery Practice. 2014;(7),29.